Back to News
Market Impact: 0.25
Cognition Therapeutics, Inc. Receives Nasdaq Deficiency Letter and Reports Third Quarter 2026 Financial Results
Source: Nasdaq
Regulation & LegislationCompany Fundamentals
Cognition Therapeutics said it received a Nasdaq deficiency letter on November 3, 2026, because its common stock closing bid price had fallen below the $1.00-per-share minimum for continued listing. The article text is truncated after stating the price had been below the threshold for “30 c,” so the full period and any further compliance details are unavailable.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly negative
Sentiment Score
-0.25
Ticker Sentiment
CGTX-0.70
More News
- Tech stocks are suffering their biggest selloff since Covid, as investors see premature end to AI datacenter boom
- Elon Musk's Tesla and SpaceX lose over $420 billion in combined market cap after midterms
- We're raising our price target on Cardinal Health after another stellar quarter of profits
- South Korea’s KOSPI halts trade after 8% wipeout on AI losses
- U.S. stock futures rise after AI rout batters Wall St; payrolls data in focus
- ’Our phones are exploding’: Goldman Sachs dissects historic Wall Street crash